Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Daratumumab was associated with impressive antitumor responses, including complete and very good partial responses, in heavily pretreated patients with myeloma. Infusion reactions were the main adverse effect. Current therapies, including proteasome inhibitors and immunomodulatory agents, have impro...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2015-09, Vol.373 (13), p.1207-1219
Hauptverfasser:	Lokhorst, Henk M, Plesner, Torben, Laubach, Jacob P, Nahi, Hareth, Gimsing, Peter, Hansson, Markus, Minnema, Monique C, Lassen, Ulrik, Krejcik, Jakub, Palumbo, Antonio, van de Donk, Niels W.C.J, Ahmadi, Tahamtan, Khan, Imran, Uhlar, Clarissa M, Wang, Jianping, Sasser, A. Kate, Losic, Nedjad, Lisby, Steen, Basse, Linda, Brun, Nikolai, Richardson, Paul G
Format:	Artikel
Sprache:	eng
Schlagworte:	ADP-ribosyl Cyclase 1 - antagonists & inhibitors Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacokinetics Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Autografts Body weight Bortezomib CD38 antigen Clinical Medicine Disease-Free Survival Dose-Response Relationship, Drug Drug Resistance, Neoplasm Female Hematologi Hematology Humans Immunomodulation Immunotherapy Klinisk medicin Male Medical and Health Sciences Medicin och hälsovetenskap Middle Aged Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Patients Pharmacokinetics Pneumonia - chemically induced Proteasome inhibitors Protein expression Signal transduction Targeted cancer therapy Thrombocytopenia Thrombocytopenia - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!